y90 dota-biotin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2017 (NCT02483000)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Payload
- 90-yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 dota-biotin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06390241 | Phase 1 | Jun 19, 2024 | Istituto Nazionale per lo Studio e la Cura dei Tumori |
| NCT02483000 | Phase 1 | Feb 1, 2017 | National Cancer Institute (NCI), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Istituto Nazionale per lo Studio e la Cura dei Tumori | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1